Subsequent Events	3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events Amendment of HutchMed License Agreement On May 6, 2022 HutchMed and the Company executed an amendment to the HutchMed License Agreement and entered into a manufacturing technology transfer and supply agreement as contemplated by the HutchMed License Agreement. For a further discussion of these agreements see Note 12, Collaborations and License Agreements. Conversion of Preferred Stock In May 2022, the holders of 337,800 shares of Series A Preferred Stock elected to convert such shares into 3,378,000 shares of the Company's common stock. As a result of the conversion, no shares of Series A Preferred Stock remain outstanding. Equity Inducement Awards On April 1, 2022, the Company granted options to purchase an aggregate of 800,000 shares of the Company's common stock to a new employee as equity inducement awards outside of the Company's 2013 Stock Incentive Plan and material to the employee’s acceptance of employment with the Company. These options have an exercise price of $1.14 per share, which is equal to the closing price of the Company's common stock on April 1, 2022, the grant date of these options. These equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), and these equity awards remain outstanding as of the date of the filing of this Quarterly Report on Form 10-Q.

Subsequent Events

3 Months Ended

Mar. 31, 2022

18. Subsequent Events

Amendment of HutchMed License Agreement

On May 6, 2022 HutchMed and the Company executed an amendment to the HutchMed License Agreement and entered into a manufacturing technology transfer and supply agreement as contemplated by the HutchMed License Agreement. For a further discussion of these agreements see Note 12, Collaborations and License Agreements.

Conversion of Preferred Stock

In May 2022, the holders of 337,800 shares of Series A Preferred Stock elected to convert such shares into 3,378,000 shares of the Company's common stock. As a result of the conversion, no shares of Series A Preferred Stock remain outstanding.

Equity Inducement Awards

On April 1, 2022, the Company granted options to purchase an aggregate of 800,000 shares of the Company's common stock to a new employee as equity inducement awards outside of the Company's 2013 Stock Incentive Plan and material to the employee’s acceptance of employment with the Company. These options have an exercise price of $1.14 per share, which is equal to the closing price of the Company's common stock on April 1, 2022, the grant date of these options. These equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), and these equity awards remain outstanding as of the date of the filing of this Quarterly Report on Form 10-Q.